Dextroamphetamine Sulfate Tablet
NDC Package 13107-035-01
Package Information
Dextroamphetamine Sulfate tablets is uSP are indicated for:1. Narcolepsy.2. Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. This formulation utilizes a tablet delivery system. Marketed by Aurolife Pharma, Llc, this product is identified by NDC 13107-035 and is authorized under FDA application ANDA202893.
Identification & Billing
- RxCUI: 884385 - dextroamphetamine sulfate 10 MG Oral Tablet
- RxCUI: 884386 - dextroamphetamine sulfate 5 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 13107 - Aurolife Pharma, Llc
- 13107-035 - Dextroamphetamine Sulfate
- 13107-035-01 - 100 TABLET in 1 BOTTLE
- 13107-035 - Dextroamphetamine Sulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (13107-035). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 13107-035-01 identifies a specific commercial package of 100 tablet in 1 bottle of Dextroamphetamine Sulfate, a human prescription drug labeled by Aurolife Pharma, Llc. This tablet is formulated for oral use and contains dextroamphetamine sulfate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Aurolife Pharma, Llc on July 31, 2013. The current certification is valid through December 31, 2027.
How is this Aurolife Pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 13107003501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.